Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Nichi-Iko Likely to Face Biz Suspension Order over Spate of Recalls
February 25, 2021
- MHLW Approves Add’l Use for Thaled, Bavencio and More
February 25, 2021
- 10,000 COVID-19 Patients Received Avigan in Observational Studies: Govt
February 25, 2021
- MHLW Formally Adopts GS1 Codes for Electronic Package Inserts; Rule to Take Effect August 1
February 25, 2021
- Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
- MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
February 25, 2021
- 4 APIs/9 Products Excluded from Kobayashi Kako Biz Suspension for Medical Needs
February 24, 2021
- MHLW Not Discussing Single-Dose Use of COVID-19 Vaccine: Minister
February 24, 2021
- Incyte’s Pemigatinib Clears PAFSC, March Approval Likely
February 24, 2021
- LDP COVID-19 Project Team to Compile Proposal on Single Vaccine Dose
February 24, 2021
- Orphan Status Granted to Novo’s Concizumab, Eisai’s E7090 and More
February 24, 2021
- LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
- Whether to Get COVID-19 Vaccines Up to Individuals to Decide: Govt
February 22, 2021
- First Possible Adverse Reactions from Pfizer Vaccine Reported in Japan
February 22, 2021
- Up to 1.17 Million Vaccine Doses to Be Shipped for HCPs in First Half of March
February 22, 2021
- Govt Plans Ticket Barcode Scan for New Vaccination Tracking System
February 18, 2021
- Japan Might Reconsider Vaccine Use for Kids under Age 16 If Data Obtained
February 18, 2021
- Celgene’s CAR-T Liso-Cel Now in Line for Possible March Approval in Japan
February 18, 2021
- Japan Launches COVID-19 Vaccination Program
February 18, 2021
- MHLW Hints It Might Take 1 Year for Kobayashi Kako to Resume Operations
February 17, 2021
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…